---
figid: PMC7527574__gr1
figtitle: Therapeutic targeting of HGF/c-Met pathway
organisms:
- Homo sapiens
- Mus musculus
- Rat sarcoma virus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7527574
filename: gr1.jpg
figlink: pmc/articles/PMC7527574/figure/f0005/
number: F1
caption: Therapeutic targeting of HGF/c-Met pathway. c-Met pathway inhibition can
  be achieved using c-Met tyrosine kinase inhibitors, like cabozantinib, tivantinib,
  and TAS-115 (black boxes), through inhibition of several signalling pathways responsible
  for promoting proliferation, migration, invasion, and metastases formation. AKT
  serine/threonine-protein kinase, AXL AXL receptor tyrosine kinase, BAD BCL2 associated
  agonist of cell death, ERK extracellular signal-regulated kinase, MEK mitogen-activated
  protein kinase kinase , mTOR mammalian target of rapamycin, NF-κB nuclear factor
  kappa B, p38 p38 mitogen-activated protein kinase, PI3K phosphoinositide 3-kinase,
  RAS rat sarcoma virus homolog, RAF RAF serine/threonine-protein kinase, SRC proto-oncogene
  tyrosine-protein kinase, STAT signal transducer and activator of transcription,
  VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor
  receptor.
papertitle: c-Met expression in renal cell carcinoma with bone metastases.
reftext: Rita Silva Paiva, et al. J Bone Oncol. 2020 Dec;25:100315.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9669915
figid_alias: PMC7527574__F1
figtype: Figure
redirect_from: /figures/PMC7527574__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7527574__gr1.html
  '@type': Dataset
  description: Therapeutic targeting of HGF/c-Met pathway. c-Met pathway inhibition
    can be achieved using c-Met tyrosine kinase inhibitors, like cabozantinib, tivantinib,
    and TAS-115 (black boxes), through inhibition of several signalling pathways responsible
    for promoting proliferation, migration, invasion, and metastases formation. AKT
    serine/threonine-protein kinase, AXL AXL receptor tyrosine kinase, BAD BCL2 associated
    agonist of cell death, ERK extracellular signal-regulated kinase, MEK mitogen-activated
    protein kinase kinase , mTOR mammalian target of rapamycin, NF-κB nuclear factor
    kappa B, p38 p38 mitogen-activated protein kinase, PI3K phosphoinositide 3-kinase,
    RAS rat sarcoma virus homolog, RAF RAF serine/threonine-protein kinase, SRC proto-oncogene
    tyrosine-protein kinase, STAT signal transducer and activator of transcription,
    VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor
    receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Hgf
  - Met
  - Axl
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Vegfa
  - Nfkb1
  - Pik3r1
  - Src
  - ras
  - Hras
  - Kras
  - Rem1
  - Akt1
  - Zhx2
  - Mtor
  - Bad
  - Ephb2
  - Mapk1
  - HGF
  - IL6
  - SOS1
  - KDR
  - FLT1
  - FLT4
  - AXL
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - NFKB1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SRC
  - FGR
  - FYN
  - YES1
  - KRAS
  - HRAS
  - NRAS
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MTOR
  - BAD
  - EPHB2
  - MAPK3
  - Pvr
  - lic
  - p38b
  - Nurf-38
  - Ebp
  - p38a
  - Hrb87F
  - p38c
  - Pvf1
  - Pvf2
  - Pvf3
  - Dif
  - dl
  - Rel
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Src42A
  - Csk
  - Src64B
  - Ras64B
  - Ras85D
  - Stat92E
  - Akt
  - Raf
  - Tor
  - cass
  - Erk7
  - rl
  - Tivantinib
  - Carbozantinib
---
